BJP CPD Online e-learning site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gerlach, J.
Right arrow Articles by Nielsen, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gerlach, J.
Right arrow Articles by Nielsen, H.

The British Journal of Psychiatry 147: 283-288 (1985)
© 1985 The Royal College of Psychiatrists

Sulpiride and haloperidol in schizophrenia: a double-blind cross-over study of therapeutic effect, side effects and plasma concentrations

J Gerlach, K Behnke, J Heltberg, E Munk-Anderson and H Nielsen

In a double-blind cross-over trial, 20 chronic schizophrenic patients were treated with sulpiride and haloperidol in two 12-week periods. The final median dose of sulpiride was 2000 mg/day (range 800-3200) and of haloperidol 12 mg/day (range 6-24). Sulpiride had an antipsychotic effect and therapeutic profile not significantly different from that of haloperidol. In spite of the high doses of sulpiride, extrapyramidal side-effects were seen less frequently during the first four weeks of the sulpiride period than during the corresponding haloperidol period (P less than 0.05), whereas autonomic side-effects were equally rare for both drugs. A positive correlation was found between daily dose and plasma concentration of both sulpiride (P less than 0.001) and haloperidol (P less than 0.05), but no correlation could be established between clinical effects and plasma levels of either neuroleptic.


This article has been cited by other articles:


Home page
 Arch Gen PsychiatryHome page
O. Agid, S. Kapur, T. Arenovich, and R. B. Zipursky
Delayed-Onset Hypothesis of Antipsychotic Action: A Hypothesis Tested and Rejected
Arch Gen Psychiatry, December 1, 2003; 60(12): 1228 - 1235.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
C. MISSALE, S. R. NASH, S. W. ROBINSON, M. JABER, and M. G. CARON
Dopamine Receptors: From Structure to Function
Physiol Rev, January 1, 1998; 78(1): 189 - 225.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
Copyright © 1985 The Royal College of Psychiatrists.